QVAR REDIHALER
Peakbeclomethasone dipropionate hfa
NDAINHALATIONAEROSOL, METERED
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QVAR REDIHALER is a metered-dose inhaler containing beclomethasone dipropionate HFA, a inhaled corticosteroid used to treat asthma and chronic obstructive pulmonary disease (COPD). The drug works by reducing airway inflammation and suppressing the immune response in the lungs. It represents a reformulation innovation of an established corticosteroid class.
$49.0MPart D
Peak15.1 years to LOEPeak-stage product with $49M in Part D spending indicates a mature, stable franchise with established commercial infrastructure and modest team size requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on QVAR REDIHALER offers stable, peak-stage pharmaceutical experience in a mature indication with strong commercial fundamentals ($49M Part D spending). However, zero linked job openings and absence of clinical expansion activity suggest this is a maintenance-focused franchise rather than a growth opportunity.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.